Autolus Therapeutics plc - American Depositary Shares (AUTL)
1.5100
-0.0600 (-3.82%)
NASDAQ · Last Trade: Apr 3rd, 4:25 PM EDT

Via Benzinga · November 15, 2024

Via Benzinga · June 17, 2024

Via Benzinga · March 18, 2024

Via Benzinga · November 12, 2024

Via Benzinga · November 11, 2024

Via Benzinga · October 2, 2024

AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 8, 2024

Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy.
Via InvestorPlace · June 13, 2024

Via Benzinga · May 17, 2024

AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 17, 2024

Via Benzinga · May 17, 2024

Via Benzinga · April 11, 2024

Via Benzinga · March 20, 2024

Via Benzinga · March 15, 2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
Via Benzinga · March 14, 2024

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer.
Via Talk Markets · January 12, 2024

Via Benzinga · December 27, 2023

Via Benzinga · November 28, 2023

Via Benzinga · November 15, 2023

Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9
Via Benzinga · August 17, 2023